Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Summary by The Manila Times
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron” or the 'Company”), a commercial-stage biotechnology company, today announced...

1 Articles

The Manila TimesThe Manila Times
Lean Right

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron” or the 'Company”), a commercial-stage biotechnology company, today announced...

·Manila, Philippines (the)
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Manila Times broke the news in Manila, Philippines (the) on Friday, January 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cary, North Carolina icon

Cary, North Carolina

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal